
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory for Cancer Research, College of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
In human trials, the method of delivery of the tea and the bioavailability of the putative effective agents in the target tissues are important issues. In many human studies, the agents are usually given in capsules or tablets, but these may not be the best methods of delivery in certain cases. Therefore, the experimental determination of blood and tissue levels of these compounds is important. We have previously developed methods and obtained data on blood and tissue levels of tea catechins [EGCG,4 EGC, and (-)-epicatechin (11) ]. In preparation for preventive trials on oral and esophageal cancers, we determined the salivary levels of tea catechins. After drinking green tea, the salivary levels of EGCG, EGC, and (-)-epicatechin in human volunteers were found to be much higher than those observed in the blood, whereas the same amount of green tea solids in capsules produced a nondetectable level of salivary tea catechins. The enzymatic conversion of EGCG to EGC was observed in the oral cavity. This enzyme activity has not been reported previously, and we tentatively named it catechin esterase or EGCG esterase. Human saliva is known to contain esterases of the carboxylesterase type, which are sensitive to the inhibition by organophosphorus compounds (12) . However, salivary EGCG esterase activity was not inhibited by bis-4-nitrophenyl phosphate. This article reports on our studies of human salivary catechins and the characterization of salivary catechin esterase activity.
| Materials and Methods |
|---|
|
|
|---|
Sample Collection.
Six healthy adult volunteers (four males and two females) who did not smoke or drink alcoholic beverages, ranged in age from 3050 years, and weighed 4585 kg participated in the study. The subjects did not ingest tea or tea-related beverages for at least 2 days before the experiment and during the urine sample collection period. The volunteers brushed their teeth thoroughly after breakfast and drank the green tea solution (1.2 g of green tea solids in 200 ml of water) in a 23-min period between 9 and 10 a.m. They immediately rinsed their mouths vigorously with water 10 times in 2 min. In other experiments, the subjects held a tea or EGCG solution in their mouths for a specified period, voided the solution, and rinsed their mouths as described above. Saliva samples from the subjects were collected into conical tubes before the dose and at different time points after the dose. The salivary sample (1 ml) was mixed with 20 µl of ascorbate-EDTA solution [0.4 M NaH2PO4 buffer containing 20% ascorbic acid and 0.1% EDTA (pH 3.6)], and the mixture was stored at -80°C until analysis. Urinary samples were collected before the dose and during periods at 03, 36, 69, 912, 1218, and 1824 h after the dose. The volume of each urinary sample was recorded. Aliquots of 20 ml of each urinary sample were transferred into plastic bottles that contained 20 mg of ascorbic acid and 0.5 mg of EDTA and then stored at -80°C until analysis. Blood samples from the subjects were collected into heparin-containing blood collection tubes at 15 and 60 min after holding an EGCG solution in the mouth for 2 min. After centrifugation, 1 ml of each plasma sample was mixed with 20 µl of the ascorbate-EDTA solution, and the mixture was stored at -80°C until analysis.
Catechin Esterase Activity.
For studying the catechin esterase activity, saliva samples (20 ml each time) were collected from volunteers and stored at -80°C. The samples were thawed after a few days and centrifuged at 16,000 x g for 5 min to remove particulates and mucous type matters. The supernatant was used as the enzyme source. The enzyme activity was assayed in a mixture containing 0.4 M sodium phosphate buffer (pH 6.8), EGCG, and saliva by incubation at 21°C and shaking for 30 min. The reaction was terminated by adding 1 ml of ethyl acetate. The ethyl acetate phase was separated and dried. The residues were redissolved in 1% ascorbic acid and analyzed by HPLC.
Sample Preparation for Catechin Analysis.
The thawed saliva (100 µl) was mixed with 10 µl of ascorbate-EDTA solution, 40 µl of 4.5% HClO4, and 350 µl of ice-cold water. A standard solution containing EGCG, EGC, and EC (500 ng of each in 50 µl) was added to a similar mixture containing the saliva collected before tea consumption. The mixture was vortex mixed for 4 min and centrifuged at 16,000 x g for 10 min, and the supernatant was then diluted, if necessary, before injection onto the HPLC.
For the analysis of urinary levels of catechins, our previous procedure was used (11) . In brief, the thawed urine was incubated with a mixture of ß-glucuronidase and sulfatase in a pH 6.8 sodium phosphate buffer to convert the conjugated catechins to the free form. The reaction mixture was extracted twice with ethyl acetate, dried, redissolved in 10% acetonitrile aqueous solution, and injected onto the HPLC.
Analysis of Tea Catechins by HPLC.
The conditions for HPLC using the NBS C18 reversed-phase column (Niko Bioscience, Inc., Tokyo, Japan) were the same as those described previously (11)
, except that the column elution conditions were modified. The column was eluted at 35°C with 96% buffer A [30 mM NaH2PO4 buffer containing 1.8% acetonitrile and 0.1% tetrahydrofuran (pH 3.35)] and 4% buffer B [15 mM NaH2PO4 buffer containing 65% acetonitrile and 6.5% tetrahydrofuran (pH 3.45)] for 5 min, followed by 82% buffer A and 18% buffer B for 23 min at a flow rate of 1 ml/min. Over the next 10 min, the solvent was changed in a linear gradient to 2% buffer A and 98% buffer B and then maintained at 2% buffer A and 98% buffer B for another 8 min. After the run, the solvent was changed back to 96% buffer A and 4% buffer B for analysis of the next sample. The eluent was monitored by the ESA Model 5500 coulochem electrode array system with potential settings at -90, -10, 70, and 150 mV, and four chromatograms were obtained simultaneously.
| Results |
|---|
|
|
|---|
|
|
Tea Catechin Levels in the Saliva, Urine, and Blood after Holding Green Tea or EGCG Solutions in the Mouth.
In the first experiment, a subject held 60 ml of green tea solution in his/her mouth for 1 or 5 min without swallowing. After voiding the tea solution, the subjects mouth was rinsed, and the saliva samples were collected as described above. The results in Fig. 3
demonstrate that holding tea in the mouth for 5 min rather than 1 min resulted in salivary EGC and EGCG levels that were four to five times higher. With a 1-min holding time, the 7 mg/ml tea solution produced higher salivary levels of catechins than did the 1.5 mg/ml solution. The t1/2 was 19.323.1 min for all three catechins. It was also noted that the EGC and EC (but not EGCG) levels at the second time-point were higher than those at the first time point. This result suggested a possible conversion of EGCG to EGC and EC in the oral cavity.
|
|
|
|
|
|
Three commonly used esterase inhibitors, which are known to inhibit different types of esterases (13) , were shown not to inhibit human salivary EGCG esterase activity (data not shown). The inhibitors and concentrations used were EDTA (0.11 mM) for arylesterase, bis-4-nitrophenyl phosphate (0.010.5 mM) for carboxylesterase, and physostigmine (0.051 mM) for cholinesterase. In the presence of physostigmine, an increase in EGCG esterase activity was observed, and at 1 mM, the activity was approximately doubled. The reason for this increase is not known. These results suggest that the EGCG esterase activity does not belong to any of these three types of esterases.
| Discussion |
|---|
|
|
|---|
Because salivary catechins were not observed when tea was taken in capsules, the rather high level of salivary catechins could not come from systemically absorbed catechins. One possible explanation for this observation is that tea catechins are absorbed p.o. and then secreted from the salivary glands into the oral cavity. Alternatively, the catechins could be bound to the surface of the oral mucosa and redissolved in the saliva. The fact that holding a tea solution in the mouth for 5 min produced a much higher salivary catechin level than holding the same amount of tea in the mouth for 1 min favors the first possibility, because absorption is a time-dependent event, and physical binding takes place readily. The time-dependent oral conversion of EGCG to EGC (Figs. 3
and 4
) and the formation of possible metabolites are also in agreement with the concept that tea catechins are absorbed p.o. and undergo biotransformation in the oral cavity. Catechin-related polyphenols are known to bind tightly to proline-rich salivary proteins (16)
. It is not clear whether the presently observed salivary proteins are in the free or bound form. It is interesting to note that at 120 min, when the salivary levels of EGC and EGCG were almost nondetectable, sizable peaks of "metabolite" peaks 2 and 4 were observed in the same HPLC run (Fig. 1)
. The fact that these peaks were also observed in urine samples in a time-dependent manner again suggests that they are metabolites of tea catechins. Recent results indicated that these urinary peaks were also observed after the ingestion of EGCG or EGC by human volunteers,5
but the identities of these peaks remain to be determined.
Oral absorption and biotransformation may also account for the plasma EGCG, EGC, and EC and the urinary EGC and EC observed after holding an EGCG solution in the mouth for 2 min (Fig. 5)
. Another possible origin of the plasma catechins is the saliva that was swallowed, and the salivary catechins are then absorbed systemically. After drinking tea, it takes about 1.5 h to observe the peak plasma level of EGCG (15)
. If the swallowed saliva was the only source of the catechins, we would expect the peak plasma EGCG level to be observed at 1.5 h after holding the EGCG solution in the mouth. The fact that the 15 min plasma level of EGCG was about two times higher than that of the 60 min plasma suggests that oral absorption is responsible for the faster delivery of EGCG to the blood. In this experiment, most of the saliva secreted in the first 20 min was collected into test tubes for the experiment (Fig. 4)
, and only a small portion of the saliva was swallowed. This further favors the concept of oral absorption of tea catechins. The observation of the EC peak in the saliva after holding an EGCG solution in the mouth is rather surprising, because the conversion of EGCG or EGC to EC involves the removal of a phenolic group that is not easily accomplished by mammalian enzymes. The chemical identity of this "EC" peak needs to be determined.
The presently observed catechin esterase activity is rather intriguing. It is apparently responsible for the oral conversion of EGCG to EGC. The lack of this activity in the blood and liver is consistent with the observation that after an oral or i.v. administration of EGCG to rats, EGC is not observed in the blood (17) . Similarly, the blood level of EGC was not observed after oral ingestion of EGCG (150 mg in 200 ml water).5 The origin of this esterase activity is still not clear. In addition to saliva secreted from the salivary glands, total saliva also contains epithelial cells, bacteria, and leukocytes. Esterase could be released from any of these types of cells. Esterase activities have been detected in human gingival epithelium and salivary glands (18, 19, 20, 21) . Esterase activity in oral microorganisms has also been described previously (22) . Judging from the fact that extensive cleaning of the mouth with a toothbrush and mouthwash solutions did not significantly affect the esterase activity, the esterase activity is likely to be due to human enzymes. The activity was not inhibited by the inhibitors of the three types of common human esterases (arylesterase, cholinesterase, and carboxylesterase) and may be due to an esterase that has not been described. The possible microbial origin of the presently observed catechin esterase, however, cannot be completely excluded.
The presently demonstrated salivary tea catechins and catechin esterase activity are important to our understanding of the bioavailability of tea catechins, especially in the oral cavity and the esophagus. In future human trials on the prevention of oral and esophageal cancer by tea, drinking a tea solution can obviously deliver much higher concentrations of tea catechins to the target tissues than using tea capsules. In addition to the initial exposure of the epithelial cells to tea during the drinking period, the levels of salivary catechins during the first couple of hours after drinking the tea are high enough to inhibit the growth of the preneoplastic cells in the oral cavity (23) and the esophageal epithelium, because we constantly swallow our saliva. Based on this analysis, the habit of drinking tea slowly may be a better practice, because it prolongs the contact time of tea with epithelial cells. Drinking tea slowly may also increase the bioavailability of tea catechin systemically because of the oral absorption of these compounds. In addition, the oral conversion of EGCG to EGC may increase the bioavailability of catechins, because the latter is more bioavailable. The higher bioavailability of EGC as compared to EGCG has been demonstrated in humans (15) , and these two catechins have similar growth inhibitory effects against human lung tumor cells (24) . For future prevention trials on oral and esophageal cancers, drinking tea slowly or using a tea mouthwash or lozenge would be effective ways to deliver tea catechins to the target tissues.
| Footnotes |
|---|
1 Supported by NIH Grant CA56673 and facilities from National Institute of Environmental Health Sciences Center Grant ES05022 and National Cancer Institute Cancer Center Support Grant CA72720. ![]()
2 To whom requests for reprints should be addressed, at Laboratory for Cancer Research, College of Pharmacy, Rutgers, The State University of New Jersey, 164 Frelinghuysen Road, Piscataway, NJ 08854-8020. ![]()
3 Present address: Department of Metabolism and Pharmacokinetics, Pharmaceutical Research Institute, Bristol-Myer Squibb Company, P. O. Box 4000, Princeton, NJ 08543-4000. ![]()
4 The abbreviations used are: EGCG, (-)-epigallocatechin-3-gallate; EGC, (-)-epigallocatechin; EC, (-)-epicatechin; HPLC, high-performance liquid chromatography; t1/2, elimination half-life. ![]()
Received 9/30/98; revised 10/16/98; accepted 10/25/98.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Zhang, C. D. J. Holman, J.-p. Huang, and X. Xie Green tea and the prevention of breast cancer: a case-control study in Southeast China Carcinogenesis, May 1, 2007; 28(5): 1074 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-S. Liu, Y.-H. Chen, P.-F. Hung, and Y.-H. Kao Inhibitory effect of green tea (-)-epigallocatechin gallate on resistin gene expression in 3T3-L1 adipocytes depends on the ERK pathway Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E273 - E281. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hsu, D. P. Dickinson, H. Qin, C. Lapp, D. Lapp, J. Borke, D. S. Walsh, W. B. Bollag, H. Stoppler, T. Yamamoto, et al. Inhibition of Autoantigen Expression by (-)-Epigallocatechin-3-gallate (the Major Constituent of Green Tea) in Normal Human Cells J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 805 - 811. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-J. Lee, J. D. Lambert, S. Prabhu, X. Meng, H. Lu, P. Maliakal, C.-T. Ho, and C. S. Yang Delivery of Tea Polyphenols to the Oral Cavity by Green Tea Leaves and Black Tea Extract Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 132 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamamoto, S. Hsu, J. Lewis, J. Wataha, D. Dickinson, B. Singh, W. B. Bollag, P. Lockwood, E. Ueta, T. Osaki, et al. Green Tea Polyphenol Causes Differential Oxidative Environments in Tumor versus Normal Epithelial Cells J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 230 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. E. Spencer Metabolism of Tea Flavonoids in the Gastrointestinal Tract J. Nutr., October 1, 2003; 133(10): 3255S - 3261. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Lambert and C. S. Yang Mechanisms of Cancer Prevention by Tea Constituents J. Nutr., October 1, 2003; 133(10): 3262S - 3267. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Cai, N. D. Anavy, and H-H. S. Chow Contribution of Presystemic Hepatic Extraction to the Low Oral Bioavailability of Green Tea Catechins in Rats Drug Metab. Dispos., November 1, 2002; 30(11): 1246 - 1249. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-J. Lee, P. Maliakal, L. Chen, X. Meng, F. Y. Bondoc, S. Prabhu, G. Lambert, S. Mohr, and C. S. Yang Pharmacokinetics of Tea Catechins after Ingestion of Green Tea and (-)-Epigallocatechin-3-gallate by Humans: Formation of Different Metabolites and Individual Variability Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1025 - 1032. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zhang, C. W. Binns, and A. H. Lee Tea Consumption and Ovarian Cancer Risk: A Case-Control Study in China Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 713 - 718. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Li, X. Chen, J. Liao, G. Yang, S. Wang, Y. Josephson, C. Han, J. Chen, M.-T. Huang, and C. S. Yang Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin Carcinogenesis, August 1, 2002; 23(8): 1307 - 1313. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Augustine Nutritionist/Dietitian Analysis Integr Cancer Ther, March 1, 2002; 1(1): 54 - 55. [PDF] |
||||
![]() |
D. L. McKay and J. B. Blumberg The Role of Tea in Human Health: An Update J. Am. Coll. Nutr., February 1, 2002; 21(1): 1 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Meng, M.-J. Lee, C. Li, S. Sheng, N. Zhu, S. Sang, C.-T. Ho, and C. S. Yang Formation and Identification of 4'-O-Methyl-(-)-Epigallocatechin in Humans Drug Metab. Dispos., June 1, 2001; 29(6): 789 - 793. [Abstract] [Full Text] |
||||
![]() |
B. A. Warden, L. S. Smith, G. R. Beecher, D. A. Balentine, and B. A. Clevidence Catechins Are Bioavailable in Men and Women Drinking Black Tea throughout the Day J. Nutr., June 1, 2001; 131(6): 1731 - 1737. [Abstract] [Full Text] |
||||
![]() |
C. S. Yang and J. M. Landau Effects of Tea Consumption on Nutrition and Health J. Nutr., October 1, 2000; 130(10): 2409 - 2412. [Abstract] [Full Text] |
||||
![]() |
S. K. Katiyar, N. Ahmad, and H. Mukhtar Green Tea and Skin Arch Dermatol, August 1, 2000; 136(8): 989 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Scalbert and G. Williamson Dietary Intake and Bioavailability of Polyphenols J. Nutr., August 1, 2000; 130(8): 2073S - 2085. [Abstract] [Full Text] |
||||
![]() |
J. Zhao and R. Agarwal Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention Carcinogenesis, November 1, 1999; 20(11): 2101 - 2108. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nam, D. M. Smith, and Q. P. Dou Ester Bond-containing Tea Polyphenols Potently Inhibit Proteasome Activity in Vitro and in Vivo J. Biol. Chem., April 13, 2001; 276(16): 13322 - 13330. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |